“Every story is different, every experience is different and how people talk about is completely different as well. But one thing that is always consistent is this is just as profound kind of enlightenment, if you will, as to they understand their disease and why they're experiencing what they have and the root of the problem, just on a really different level.” – Joshua Bartch In today’s episode, we welcome Joshua Bartch, he is the Director, Chief Executive Officer, and Chairman of Mydecine Innovations Group (MIG). Joshua’s entrepreneurial career took off in 2009 when he co-founded AudioTranscriptionist.com and founded a boutique investment firm that operated through the U.S. and Canadian markets. In 2014, Bartch co-founded Cannabase.io, the U.S.’s most significant legal and sophisticated cannabis wholesale platform. He took successful exits from AudioTransciptionist.com, Doctor’s Orders, and Cannabase.io. In this conversation, Joshua’s goal is to bring more effective treatments to those who need them most. He found that current treatments are not effective and that this is a major focus of their work. [00:01 - 07:26] Who is Josh Bartch? Zack introduces his guest Josh Bartch Josh talks about his company, Mydecine, a biotechnology company which is focused on mental disorders and addiction He talks about assembling a team with extensive background on drug development in order to drive a successful company Mydecine is developing a drug to help smokers quit, based on the molecule psilocybin, which the active component of medicinal mushrooms The drug is being developed in partnership with https://www.jhu.edu/ (Johns Hopkins)

[07:27 - 13:06] On A Mission To Educate Veterans About The Potentials Benefits of Psychedelics Josh acknowledges the contributions of https://www.mydecine.com/news-media/press-releases/detail/84/mydecines-chief-medical-officer-dr-rakesh-jetly-to (Dr. Rakesh) After numerous months of research, they found that most of the population was biologically verified completely absent from smoking They aim to combat stress with a focus on working with veterans’ organizations His team is focused on developing treatments for PTSD in veterans, which is a population that is particularly resistant to treatment Their studies show how psychedelics may be able to play a role in treating these conditions Josh discusses how the team has been successful in getting veterans organization on board with their mission and educating them about the potential benefits of treatments using psychedelics

[13:07 - 17:51] Overcoming The Stigma Associated With Psychedelic Treatments Josh understands that people have been through different things, whether it’s PTSD or trauma-related or have become addicted to different aspects of things How Josh is reaching out to Alpha-types  As soldiers, they are taught to be tough and they would need a therapist to penetrate through the brain Mydecine’s goal is to get the general medical community to think that prescribing clinicians will prescribe psychedelics, and it has put out a media platform to do this It offers guided meditations and other ancillary services to its users Josh discusses the challenges and stigma associated with psychedelic treatment and how Johns Hopkins is working to overcome these obstacles

[17:52 - 30:22] The Importance of Changing Public Perception of Psychedelics Josh emphasizes the importance of changing public perception of psychedelics in order to facilitate wider acceptance and use He knows a lot of people suffers from addiction and addiction is a huge problem in society Josh discusses the business side of psychedelics that it is different pharmaceuticals but the treatment is the same Josh’s company is daring big pharma to catch up in order treat people to make medicine bills inexpensive

[30:23 - 30:44] Closing Segment Josh shares that his organization’s goal is to help people with PTSD and other mental health issues, and they...